

## SIERRA LEONE Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Sierra Leone						
<b>2. Grant number:</b> 09-SLE-8b-Y; 1821-SLE-12d-X; 18-SLE-25a-Y						
<b>3. Date of Decision Letter:</b> 10 October 2018						
<b>4. Date of the Partnership Framework Agreement:</b> 10 March 2013						
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine						
<b>6. Vaccine type:</b> Pneumococcal						
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID						
<b>8. Programme duration<sup>1</sup>:</b> 2010 - 2021						
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2010-2017	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	23,970,527 <sup>3</sup>	3,086,000	3,231,000	3,456,500	3,567,500	37,311,527
<b>10. Vaccine introduction grant / Product switch grant (in US\$):</b> A VIG of US\$ 100,00 was disbursed to Sierra Leone on 28 May 2010. <b>Sierra Leone is eligible for a Product Switch Grant of US\$ 75,533 to support the PCV switch.</b>						
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>						
Type of supplies to be purchased with Gavi funds in each year	2010-2017		2018			
Number of Pneumococcal vaccines doses			919,000			
Annual Amounts (US\$)	23,970,527 <sup>5</sup>		3,086,000			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-SLE-32a-X; 18-SLE-32a-X; 19-SLE-32a-X; 20-SLE-32a-X; 21-SLE-32a-X):

<b>New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine</b>	<b>2018</b>
Number of AD syringes	977,700
Number of re-constitution syringes	
Number of safety boxes	10,775
Annual Amounts for injection safety devices for Vaccine (US\$)	44,500

**12. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.

**13. Self-procurement:** Not applicable.

**14. Co-financing obligations:** Reference code: 1821-SLE-12d-X-C  
According to the co-financing policy, the Country falls within the group Initial self-financing.  
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	64,200	64,600	66,600	68,800
Value of vaccine doses (US\$)	195,461			
Total co-financing payments (US\$) (including freight)	197,000	198,000	204,000	211,000

<b>15. Operational support for campaigns:</b> Not applicable	
<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

On behalf of Gavi



Hind Khatib-Othman  
Managing Director, Country Programmes

10 October 2018